Anti-CD22 (Inotuzumab)-DIBO-doxorubicin ADC (CAT#: ADC-037LCT)

• Antibody Overview
• Humanized monoclonal Antibody (Anti-CD22)

• Clone
• Inotuzumab

• Linker
• DIBO (dibenzylcyclooctynol)

• Drug
• doxorubicin

• Drug Class/Description
• Doxorubicin is the generic name for the trade name drug, Adriamycin®, as well as, Rubex®, which is a type of anti-cancer chemotherapy drug called an anthracycline. Doxorubicin works by blocking an enzyme called TopoisomeraseⅡthat cancer cells need to divide and grow.

• Introduction
• CD22, or cluster of differentiation-22, is a molecule belonging to the SIGLEC family of lectins. It is found on the surface of mature B cells and to a lesser extent on some immature B cells. Generally speaking, CD22 is a regulatory molecule that prevents the overactivation of the immune system and the development of autoimmune diseases.
  CD22 is a sugar binding transmembrane protein, which specifically binds sialic acid with an immunoglobulin (Ig) domain located at its N-terminus. The presence of Ig domains makes CD22 a member of the immunoglobulin superfamily. CD22 functions as an inhibitory receptor for B cell receptor (BCR) signaling. It is also involved in the B cell trafficking to Peyer's patches in mice.

• Alternative Names
• CD22; CD22 molecule; SIGLEC2; SIGLEC-2; B-cell receptor CD22; BL-CAM; CD22 antigen; T-cell surface antigen Leu-14; B-lymphocyte cell adhesion molecule; sialic acid binding Ig-like lectin 2; sialic acid-binding Ig-like lectin 2;

• Gene ID
• 933

• UniProt ID
• P20273

• TAB-198
• Humanized Anti-CD22 Recombinant Antibody (clone Inotuzumab)

• ADC-036LCT
• Anti-CD22 (Inotuzumab)-hydrazone-Calicheamicin ADC

• ADC-L024
• Anti-CD22 (Inotuzumab)-calicheamicin ADC (CMC-544/inotuzumab ozogamicin)

Select a product category from the dropdown menu below to view related products.